Effects of CYP2C9 polymorphism on the pharmacokinetics of irbesartan in healthy Korean subjects

被引：0
|
作者：
Kim, Mi-Jung
Bae, Jung -Woo
Han, Ho-Kyun
Choi, Sun-Ok
Kim, Ok-Hee
Jang, Choon-Gon
Lee, Jin-Hee
Kim, Nam-Tae
Lee, Seok-Yong
机构：
[1] Sungkyunkwan Univ, Coll Pharm, Seoul, South Korea
[2] Natl Inst Toxicol Res, Seoul, South Korea
来源：
ACTA PHARMACOLOGICA SINICA | 2006年 / 27卷
关键词：
Irbesartan; CYP2C9; polymorphism; pharmacokinetics;
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
引用
收藏
页码：231 / 231
页数：1
相关论文
共 50 条
  • [31] The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers
    Meadowcroft, AM
    Williamson, KM
    Patterson, JH
    Hinderliter, AL
    Pieper, JA
    JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (04): : 418 - 424
  • [32] Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics
    Lee, H. W.
    Lim, M. -S.
    Lee, J.
    Jegal, M. -Y.
    Kim, D. -W.
    Lee, W. -K.
    Jang, I. -J.
    Shin, J. -G.
    Yoon, Y. -R.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (01) : 105 - 111
  • [33] The genetic analysis of CYP2C9 polymorphism in a Korean population.
    Yoon, YR
    Shon, JH
    Lee, HR
    Cha, IJ
    Shin, JG
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 184 - 184
  • [34] Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects
    Lu, Sijie
    Nand, R. A.
    Yang, J. S.
    Chen, Gang
    Gross, A. S.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (03) : 285 - 296
  • [35] Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects
    Sijie Lu
    R. A. Nand
    J. S. Yang
    Gang Chen
    A. S. Gross
    European Journal of Clinical Pharmacology, 2018, 74 : 285 - 296
  • [36] Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes
    Niemi, M
    Cascorbi, I
    Timm, R
    Kroemer, HK
    Neuvonen, PJ
    Kivistö, KT
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (03) : 326 - 332
  • [37] The pharmacokinetics of S-warfarin in healthy subjects carrying different CYP2C9 genotypes.
    Shaoul, H.
    Blotnick, S.
    Muszkat, M.
    Caraco, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S19 - S19
  • [38] Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects
    Sekino, K
    Kubota, T
    Okada, Y
    Yamada, Y
    Yamamoto, K
    Horiuchi, R
    Kimura, K
    Iga, T
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (8-9) : 589 - 592
  • [39] Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects
    Kazuishi Sekino
    Takahiro Kubota
    Yuko Okada
    Yasuhiko Yamada
    Koujirou Yamamoto
    Ryuya Horiuchi
    Kenjirou Kimura
    Tatsuji Iga
    European Journal of Clinical Pharmacology, 2003, 59 : 589 - 592
  • [40] Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects
    Cho, Chang-Keun
    Byeon, Ji-Young
    Kang, Pureum
    Park, Hye-Jung
    Ko, Eunvin
    Mu, Chou Yen
    Jang, Choon-Gon
    Lee, Seok-Yong
    Lee, Yun Jeong
    ARCHIVES OF PHARMACAL RESEARCH, 2023, 46 (02) : 111 - 116
12345